Latest Ratios: P/E Ratio -12.6x · EV/EBITDA N/A · ROE -0.9%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $101M | $166M | $69M | $158M | $345M | $3.6B | $3.2B | — | — | — |
| Enterprise Value | $72M | $136M | $-400895871 | $-129486256 | $-2830797744 | $3.1B | $-1516387173 | — | — | — |
| P/E Ratio → | -12.63 | — | — | — | — | — | 6.83 | — | — | — |
| P/S Ratio | — | — | — | 35.25 | — | 40.89 | 2.09 | — | — | — |
| P/B Ratio | 2.55 | 5.02 | 0.05 | 0.65 | 0.11 | 5.03 | 0.57 | — | — | — |
| P/FCF | — | — | — | — | — | — | 7.57 | — | — | — |
| P/OCF | — | — | — | — | — | — | 7.43 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | -28.87 | — | 34.81 | -0.98 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | -9.01 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | -9.75 | — | — | — |
| EV / FCF | — | — | — | — | — | — | -3.56 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 47.3% | 100.0% | 100.0% | 100.0% | 102.6% |
| Operating Margin | — | — | — | -11395.1% | 3422.2% | -2353.1% | 10.1% | -4883.2% | -847.4% | -2431.2% |
| Net Profit Margin | — | — | — | -32674.0% | 9044.6% | -2648.7% | 30.5% | -4826.8% | -749.0% | -2647.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.9% | -0.9% | -19.0% | -90.2% | -52.0% | -73.5% | 26.2% | — | — | -41.6% |
| ROA | -0.8% | -0.8% | -16.9% | -66.0% | -39.1% | -64.7% | 11.7% | -70.4% | -23.7% | -29.1% |
| ROIC | -2.0% | -2.0% | -59.1% | — | -4298.6% | -291.0% | 13.1% | — | — | — |
| ROCE | -1.8% | -1.8% | -41.7% | -27.4% | -17.5% | -63.4% | 4.5% | -92.2% | -31.9% | -33.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | 0.00 | — | — | 0.30 |
| Debt / EBITDA | — | — | — | — | — | — | 0.11 | — | — | — |
| Net Debt / Equity | — | -0.90 | -0.32 | -1.19 | -1.06 | -0.75 | -0.84 | — | — | -0.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | -28.16 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -11.14 | — | — | — |
| Interest Coverage | — | — | — | -3412.93 | — | — | 1062.06 | -484.44 | -258.01 | -325.05 |
Net cash position: cash ($30M) exceeds total debt ($438458)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.09 | 8.09 | 20.90 | 5.67 | 5.50 | 7.66 | 9.28 | 2.31 | 5.88 | 3.54 |
| Quick Ratio | 8.09 | 8.09 | 20.90 | 5.67 | 5.62 | 7.62 | 9.28 | 2.41 | 5.88 | 3.54 |
| Cash Ratio | 7.84 | 7.84 | 20.51 | 5.36 | 5.23 | 6.85 | 8.31 | 1.99 | 5.33 | 2.94 |
| Asset Turnover | — | — | — | 0.01 | -0.00 | 0.10 | 0.24 | 0.02 | 0.02 | 0.01 |
| Inventory Turnover | — | — | — | — | — | 10.87 | — | — | — | — |
| Days Sales Outstanding | — | — | — | 149.15 | -164.17 | 252.74 | 84.68 | 672.48 | 63.55 | 134.43 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 14.6% | — | — | — |
| FCF Yield | — | — | — | — | — | — | 13.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 3.5% | 5.5% | 0.9% | 0.0% | 0.2% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 3.5% | 5.5% | 0.9% | 0.0% | 0.2% | — | — | — |
| Shares Outstanding | — | $42M | $81M | $83M | $83M | $76M | $68M | $58M | $58M | $58M |
Critical Liquidity and Dilution
According to recent market data, NovaBridge Biosciences trades at a price-to-book ratio of 2.07, a valuation that appears to heavily discount the company's platform potential while reflecting the significant execution risks inherent in its post-divestiture transition to a streamlined, US-focused clinical-stage biotechnology entity.
The current P/B multiple suggests that investors are assigning limited value to the company's intangible assets, likely due to the binary nature of its clinical pipeline and the recent corporate rebranding. This valuation level warrants caution, as it may not fully account for the potential dilution required to fund ongoing trials given the company's constrained cash position.
As reported in financial statements, NovaBridge Biosciences has struggled with negative returns on invested capital, with the most recent quarterly ROIC of -0.9% highlighting the company's inability to generate positive economic value from its heavy R&D spending during this pre-commercial phase of development.
The persistent negative ROIC trend indicates that capital is being consumed by clinical trial infrastructure rather than being compounded through productive asset utilization. Investors should monitor whether future milestone payments can improve these returns, though current figures suggest a structural reliance on external financing to maintain operations.
Based on the 2025Q4 balance sheet, the company's current ratio of 8.09 appears superficially strong, yet this metric masks a precarious reality where the absolute cash balance of $30.1 million provides a very limited buffer against the high burn rates associated with oncology clinical trials.
While the high current ratio suggests an absence of immediate short-term debt pressure, it fails to account for the rapid cash depletion required to sustain the company's bispecific antibody programs. This liquidity profile implies that the company may face significant financing hurdles if clinical milestones are delayed or if market conditions for equity raises deteriorate.
As indicated by comparative market data, NovaBridge Biosciences' valuation metrics, including its P/B ratio of 2.07, remain significantly lower than peers like Immunovant or Arcutis, suggesting that the market is applying a structural discount to the company's post-divestiture business model compared to its industry counterparts.
This valuation gap appears to stem from the company's recent corporate restructuring and the resulting uncertainty regarding its long-term clinical execution. While the discount might present a non-consensus opportunity, it also reflects the market's skepticism regarding the company's ability to compete for capital against better-funded peers in the bispecific antibody space.
Investors frequently misapply the current ratio to evaluate NovaBridge Biosciences, as this liquidity metric obscures the company's true operational vulnerability by failing to account for the high, non-discretionary cash burn required to sustain clinical trials in a pre-revenue, high-cost biotechnology environment.
The current ratio provides a false sense of security by ignoring the velocity of cash consumption, which is the most critical metric for a pre-commercial firm. A more appropriate analytical focus would be the 'cash runway' in months, which better captures the urgency of the company's need for future capital infusions or milestone-driven liquidity.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NBP stock.
NovaBridge Biosciences's current P/E ratio is -12.6x. The historical average is 6.8x.
NovaBridge Biosciences's return on equity (ROE) is -0.9%. The historical average is -35.8%.
Based on historical data, NovaBridge Biosciences is trading at a P/E of -12.6x. Compare with industry peers and growth rates for a complete picture.